By identifying the downstream signaling pathways and effectors regulated by LCN2, this study aims to propose novel molecular targets, such as TOP2A, CDCA7, and STAT1, that could lead to innovative therapeutic strategies for treating HER2+IBC and potentially overcome the current treatment limitations, such as Herceptin resistance. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.